All In Biotech

Investigational drug · Phase 3

SIM0270

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Breast Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "SIM0270"

First trial start

2024

Nov 14, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SIM0270", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Locally Advanced or Metastatic Breast Cancer

Approved drugs for the same conditions: Breast cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "SIM0270" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Locally Advanced or Metastatic Breast Cancer

  • GiredestrantRO7197597, GDC-9545Phase 316 trials

    Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • LHRH AgonistPhase 36 trials

    Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

  • LasofoxifeneAZU-101Phase 34 trials

    Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer

  • SPH4336Phase 34 trials

    Shanghai Pharmaceuticals Holding Co., Ltd · Locally Advanced or Metastatic Breast Cancer, Breast Cancer Brain Metastases, Advanced Solid Tumors

  • MediLink Therapeutics (Suzhou) Co., Ltd. · NSCLC, Breast Cancer, HNSCC

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.